Faculty Opinions recommendation of Thymidine kinase 2 mutations in autosomal recessive progressive external ophthalmoplegia with multiple mitochondrial DNA deletions.

Author(s):  
Anders Oldfors ◽  
Ali-Reza Moslemi
2010 ◽  
Vol 33 (3) ◽  
pp. 231-236 ◽  
Author(s):  
Xiaoshan Zhou ◽  
Magnus Johansson ◽  
Nicola Solaroli ◽  
Björn Rozell ◽  
Alf Grandien ◽  
...  

1997 ◽  
Vol 4 (2) ◽  
pp. 163-168 ◽  
Author(s):  
Marie J.B Jean-Francois ◽  
Steve Collins ◽  
Nicky Kotsimbos ◽  
Xenia Dennett ◽  
Edward Byrne

2020 ◽  
Author(s):  
Carlos Lopez-Gomez ◽  
Maria J. Sanchez-Quintero ◽  
Eung Jeon Lee ◽  
Gulio Kleiner ◽  
Jun Xie ◽  
...  

AbstractAutosomal recessive thymidine kinase 2 (TK2) mutations causes TK2 deficiency, which typically manifests as a progressive and fatal mitochondrial myopathy in infants and children. Treatment with deoxycytidine and thymidine ameliorates mitochondrial defects and extends lifespan of Tk2 knock-in mouse (TK2−/−); however, efficacy is limited by age- and tissue-dependent expression of the cytosolic enzymes Tk1 and Dck. Thus, therapies aimed at systemic restoration of TK2 activity are needed. Here, we demonstrate that delivery of human TK2 cDNA to Tk2−/− mice using AAV9 efficiently rescued Tk2 activity in all the tissues tested except kidney, delayed disease onset, and increased lifespan. Sequential treatment of Tk2−/− mice with AAV9 first followed by AAV2 at different ages allowed us to reduce the viral dose while further prolonging the lifespan. Furthermore, addition of deoxycytidine and deoxythymidine supplementation to AAV9 + AAV2 treated Tk2−/− mice dramatically improved mtDNA copy numbers in liver and kidney, animal growth, and lifespan. These data indicate that combined pharmacological and gene therapies may be highly efficacious for human TK2 deficiency.


2020 ◽  
Vol 10 (11) ◽  
pp. 766 ◽  
Author(s):  
Nicole Anteneová ◽  
Silvie Kelifová ◽  
Hana Kolářová ◽  
Alžběta Vondráčková ◽  
Iveta Tóthová ◽  
...  

Background: In this retrospective study, we analysed clinical, biochemical and molecular genetic data of 47 Czech patients with Single, Large-Scale Mitochondrial DNA Deletions (SLSMD). Methods: The diagnosis was based on the long-range PCR (LX-PCR) screening of mtDNA isolated from muscle biopsy in 15 patients, and from the buccal swab, urinary epithelial cells and blood in 32 patients. Results: A total of 57% patients manifested before the age of 16. We did not find any significant difference between paediatric and adult manifestation in either the proportion of patients that would develop extraocular symptoms, or the timespan of its progression. The survival rate in patients with Pearson Syndrome reached 60%. Altogether, five patients manifested with atypical phenotype not fulfilling the latest criteria for SLSMD. No correlation was found between the disease severity and all heteroplasmy levels, lengths of the deletion and respiratory chain activities in muscle. Conclusions: Paediatric manifestation of Progressive External Ophthalmoplegia (PEO) is not associated with a higher risk of multisystemic involvement. Contrary to PEO and Kearns-Sayre Syndrome Spectrum, Pearson Syndrome still contributes to a significant childhood mortality. SLSMD should be considered even in cases with atypical presentation. To successfully identify carriers of SLSMD, a repeated combined analysis of buccal swab and urinary epithelial cells is needed.


Sign in / Sign up

Export Citation Format

Share Document